TORONTO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or
“Scythian”) (TSXV:SCYB) (Frankfurt:9SB) (OTC Pink:SCCYF) is pleased to announce that it has appointed Ottis Jerome
“O.J.” Anderson to its Pro Athlete Advisory Committee.
“We are proud to introduce Mr. Ottis Jerome “O.J.” Anderson as the second member of our Pro Athlete Advisory
Committee. Mr. Anderson was NFL Offensive Rookie of the Year in 1979, and MVP Super Bowl XXV in 1991 when he helped the New
York Giants win the championship. We are honored to have Mr. Anderson join our Pro Athlete Advisory Committee.”
“We would also like to congratulate Mr. Bart Oates, who chairs our Pro Athlete Advisory Committee for his recent
appointment as the President of the NFL Alumni Association. Mr. Oates has been the President of the NY/NJ chapter of the NFL Alumni
for several years and we certainly expect that he will continue to do a terrific job now as head at a national level,” stated Mr.
Jonathan Gilbert, CEO.
About Mr. Anderson
Ottis “O.J.” Anderson attended the University of Miami on a full athletic scholarship and earned a degree in Physical Education. He
was drafted by the St. Louis Cardinals in 1979. Mr. Anderson went on to become the first rookie running back ever to average 100
yards per game and was named the NFL's Most Valuable Player, NFL Rookie of the Year, and All-Pro that year and was named All-Pro
again in 1980 and 1981. Mr. Anderson was traded to The New York Football Giants in October of 1986. Mr. Anderson powered the team
through the playoffs and the Super Bowl XXV championship game in 1991 which earned him the title of MVP.
Stock Options and DSU’s
The Company has also issued an additional 8,750 stock options with an exercise price of $8.65 per share for a period of five years,
as well as 56,250 deferred share units to officers of the Company. Mr. Anderson also received 2,500 options with an exercise price
of $8.00 per share, for a period of five years. The options are subject to certain vesting provisions and subject to
regulatory approval.
About Scythian Biosciences Corp.
Scythian is a research and development company committed to finding a solution for the prevention and treatment
of concussions and traumatic brain injury with its proprietary Cannabinoid combination.
Scythian’s mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently
formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and
clinical trials of its drug regimen. The University of Miami believes that Scythian’s scientific approach shows significant
promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami
allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian’s
clinical studies to be undertaken at their world-class facilities.
Gillian A. Hotz, PhD, is leading Scythian’s program at the University of Miami. Dr. Hotz is a nationally
recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has
extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of
Medicine’s Concussion Program since 1995.
Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.
Contact Information
For further information, please contact:
Scythian Biosciences Corp.
Jonathan Gilbert, CEO
Phone: (212) 729-9208
Email: info@scythianbio.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statements
This press release may contain certain forward-looking information and statements
(“forward-looking information”) within the meaning of applicable Canadian securities legislation,
that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates",
"plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions.
Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may
differ materially from those contemplated by these statements. The Company undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in respect of the Company, its securities, or financial or
operating results (as applicable). Although the Company believes that the expectations reflected in forward-looking
information in this press release are reasonable, such forward-looking information has been based on expectations, factors and
assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain
of which are beyond the Company’s control, including the risk factors discussed in the Filing Statement which are incorporated
herein by reference and are available through SEDAR at www.sedar.com. The forward-looking information contained
in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company
disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking
information, whether as a result of new information, future events or otherwise.
